possible for 19 of the 25 patients studied. Five patients were alive without recurrence at last follow-up evaluation; one patient was lost to follow-up review. The definition of recurrence was based on clinical or radiological evidence of tumor growth. The location and time to metastasis, if present, were also noted ( Fig. 1) .
Sixteen computerized tomography (CT) scans and nine magnetic resonance (MR) images from 23 patients were available for study. The CT scans were analyzed for tumor density, presence of calcification, presence of cysts, degree of edema (graded from 0 to +++), enhancement characteristics, mushrooming (presence of a prominent pannus of tumor extending well away from the globoid mass), 22 hyperostosis, and any other bone or soft tissue involvement. In addition, MR imaging was used to determine the presence of a dural tail 17 and to evaluate the signal intensity of the tumor on T 1 -weighted and T 2 -weighted sequences. 
Histopathological Criteria
The criteria used to evaluate the histopathology of the tumors were in accordance with the guidelines provided by the World Health Organization for malignant meningiomas. 25, 29, 30, 38, 39 Individual histological features that have been associated with aggressive tumor behavior were examined for each patient. 2, 29, 39 These included cellularity, pleomorphism, brain invasion, mitotic activity, necrosis, sarcoma-like areas, sheeting, prominent nucleoli, and hemangiopericytic pattern. The presence or absence of each feature was noted, as well as the presence or absence of meningothelial whorls. Cellularity and pleomorphism were graded as low, moderate, or high. Mitotic activity was noted as rare or frequent, with an activity greater than one mitosis per 20 high-power fields designated as frequent.
Tumors were separated into four groups based on these histological features: atypical meningioma, malignant meningioma, meningeal sarcoma, or hemangiopericytoma. The atypical variety of meningioma may have some of the aforementioned histological features, but generally it retains typical meningothelial whorls, usually does not show brain invasion, and has only small foci of necrosis. It tends to have high cellularity, abundant mitotic activity, no areas of sarcoma-like appearance, sheeting growth patterns, and numerous nuclei with prominent nucleoli (Fig. 2) .
Malignant meningioma was diagnosed in cases in which areas of typical meningioma, such as whorls, psammoma bodies, and oval bland nuclei were present in conjunction with sarcomatous areas, more extensive necrosis, or brain invasion (Fig. 3 left) . The main features used to differentiate malignant from atypical meningioma were: 1) brain invasion, 2) sarcomatous areas, and 3) extreme degrees of the histological features associated with aggressive tumor behavior. Even so, this differentiation remains subjective and continues to be a difficult histopathological determination. A tumor was classified as a meningeal sarcoma if it resembled a spindle-cell sarcoma with a high mitotic rate. In these tumors, no areas were noted that resembled typical meningioma ( center). A hemangiopericytoma of the meninges was diagnosed by the presence of short plump spindle cells, moderate pleomorphism, and gaping or branching vascular channels surrounded by small bland tumor cells (Fig. 3  right) .
A bromodeoxyuridine (BUdR) labeling index (LI) was available for eight of the tumors studied. 10 Permission to administer BUdR was received from the Surveillance Committee of The University of Texas M. D. Anderson Cancer Center and the National Center Institute. Each patient was required to sign a consent form. The BUdR was given as a 30-minute intraoperative infusion at a dose of 200 mg/m 2 before tumor removal. Tumor specimens were fixed in 10% formalin and embedded in paraffin. Tissue sections were reacted with a monoclonal antibody* to BUdR; the indirect immunoperoxidase method was used. The BUdR LI was determined by counting at least 1000 cells, and the number was expressed as the percentage of labeled nuclei per total nuclei counted ϫ 100.
Tumors that recurred and progressed histologically by the time of this review were recorded according to their most recent diagnosis. Benign meningiomas were excluded.
Estimates of survival and freedom from recurrence rates were computed using the Kaplan-Meier method. Median times to death or recurrence were computed from the Kaplan-Meier estimates using linear interpolation. The confidence intervals were computed using the exact binomial method, with an effective sample size equal to the number of patients remaining at risk divided by the estimated probability. The distributions of time to death and time to recurrence were compared using the Cox-Mantel log-rank test. All probability values were two-tailed, and probability values less than 0.1 were considered statistically significant. Even with this increased threshold for significance, some of the comparisons may have lacked adequate statistical power because of the small number of patients involved; thus, the lack of significance should not be taken to mean that the groups had comparable results. Also, because of the retrospective, uncontrolled nature of the study, any or all of the results could be due to the confounding influences of one or more unobserved factors. The software used for the statistical analyses was BMDP1L. †
Results

Histopathological Evaluation
The histopathological characteristics found in each tumor type are summarized in Table 1 . Frequent mitoses were discovered in all but two cases in the series. A moderate to high degree of pleomorphism was also found in the vast majority of cases. Of the 12 malignant meningiomas, brain invasion and necrosis were seen in nine and 10 patients, respectively. Although invasion of the brain is often considered an absolute indicator of a malignant meningioma, one patient with brain invasion had a tumor with low cellularity and only moderate pleomorphism, thus warranting a diagnosis of atypical meningioma. Brain invasion was not noted in the meningeal sarcomas or hemangiopericytomas in this series. Necrosis was present in all meningeal sarcomas but in none of the hemangiopericytomas. No prominent nucleoli or sheeting were found in meningeal sarcomas or hemangiopericytomas.
Bromodeoxyuridine Labeling Index
Of the eight subjects who had a proliferative index determined by BUdR LI, seven had a BUdR LI greater than or equal to 1% (Fig. 1 ). All seven were diagnosed as having either meningeal sarcoma, atypical meningioma, or malignant meningioma. The one patient with a BUdR LI less than 1% (0.3%) had a hemangiopericytoma. The follow-up time was too short to note recurrence in five patients studied with BUdR. Two of the three patients with tumor recurrence underwent BUdR labeling analysis at two separate presentations of tumor, and one of these two (Case 16) showed a marked change in the BUdR LI on recurrence, decreasing from 5.8% at the time of the primary tumor resection to 2.0% at the time of resection for a second recurrence. The patient subsequently had a third recurrence, at which time an LI of 6.2% was determined despite intervening aggressive chemotherapy. No LI was available for the first recurrence. The decrease in LI between primary tumor and second recurrence may have been due to the radiation therapy that was given after the first recurrence, although the effect of radiation therapy on cell-cycling proteins is unknown. In fact, Case 19 showed no significant decrease in BUdR LI between first recurrence (LI = 3.1%) and second recurrence (LI = 2.8%) despite interval radiotherapy.
Distribution of Age and Sex
The median age of the patients reviewed was 52 years, with a range of 13 to 73 years (Table 2) . Unlike benign meningiomas, the malignant meningiomas in our series showed a marked preponderance in males (67%).
Tumor Location
Tumors were located along the cerebral convexities (12) , in the parasagittal and falcine areas (seven), in the skull base (three), in the posterior fossa (two), and in the left middle cranial fossa (one). Location did not vary by tumor type.
Radiological Studies
The results of the radiological studies are shown in Table 3 . Only malignant meningiomas demonstrated a notable number of areas with hyperintensity and indistinct margins (Fig. 4) .
Tumor calcification was not found in any of the cases, and the presence of cysts was rare. Most tumors were associated with edema, although none was found in the hemangiopericytomas (Fig. 5) . Five of 12 malignant and three of six atypical meningiomas demonstrated moderate edema (++). No tumor had a severe degree of edema (+++). At least one dural tail was found in each tumor group except the hemangiopericytomas.
Mushrooming was present in five of 12 malignant meningiomas (Fig. 6) , four of six atypical meningiomas, and two of three meningeal sarcomas. None was found in the hemangiopericytomas.
Hyperostosis appeared in only one case in this series, whereas osteolysis appeared in six cases, with at least one instance in each histopathological subtype (Fig. 7) .
Meningeal sarcomas and malignant meningiomas tended to have decreased signal intensity on T 1 -weighted MR imaging. On T 2 -weighted MR, they became hyperintense. The only atypical meningioma studied using MR was isointense on both T 1 -weighted and T 2 -weighted images.
Homogeneous enhancements were found in 10 cases, and heterogeneous enhancements in 13 cases. There was no statistical difference in enhancement among the four histological subtypes.
Therapy, Recurrence, and Survival
Follow-up time was defined as the time from first clinical presentation of tumor to the date of expiration or last contact. Of the 25 patients, 10 were still alive at least contact. The median follow-up time for all patients was 41 months (range 3 to 156 months). Twenty of 25 patients experienced tumor recurrence. The median follow-up time for these patients was 47 months (range 5 to 156 months). Median follow-up time for the five who have not had recurrences is 17 months (range 3 to 82 months). Of these five, at last contact, only one patient had died of causes unknown. The remaining four are still alive and remain at risk for recurrence. Patients with hemangiopericytoma or atypical meningioma lived longer than those with malignant meningioma or meningeal sarcoma (Fig. 8A) . Our data show that recurrences occurred more rapidly in patients with atypical meningioma or meningeal sarcoma than in patients with malignant meningioma and hemangiopericytoma (Fig. 8B) . Table 4 lists the 5-year survival and 2-year freedom from recurrence data by histopathological groups.
Of the 25 patients, four had a subtotal resection on first presentation of tumor and 21 underwent a total resection. Recurrence was noted sooner in patients who had partial resections on first presentation of tumor (median 5 months, range 4 to 19 months) than in those who had total resections at first presentation (median 35 months, range 3 to 73 months) (Fig. 8C) . Survival time was also shorter for patients who underwent partial resections at first presentation (median 46 months, range 5 to 46 months) than for patients who underwent total resections (median 130 months, range 3 to 156 months) (Fig. 8D) .
Radiation therapy was delivered to 18 of the 25 patients. Nine of these 18 underwent radiotherapy after their first surgical resection. The mean dose received was 52 Gy over 4.8 weeks, with ranges from 31 to 60 Gy in 4 to 8 weeks. Statistical analysis showed no significant differences in times to recurrence or survival durations among patients who were or were not given radiotherapy ( Fig. 8E  and F) .
Ten patients received chemotherapy. Typical regimens used included intraarterial or intravenous cisplatin, intravenous dacarbazine, and intravenous doxorubicin. None of these patients showed noticeable clinical improvement or decrease in tumor volume that could be attributed to chemotherapy.
Extracranial Metastasis
Six (24%) of the 25 patients exhibited extracranial metastases (Table 5 , Fig. 1 ). They were treated with a combination of chemotherapy and radiotherapy for metastases (three patients), chemotherapy alone (two patients), or partial resection followed by radiotherapy (one patient). The median time to metastasis was 102 months with a 95% confidence interval (96%, 102%). The 5-year metastasis-free rate was 85% with 95% confidence interval (48%, 98%). The most common sites of metastasis were lung (five of six) and bone (four of six). Case 6, which involved a meningeal sarcoma, exhibited diffuse metastases to multiple organs 3 months after the first operation. 
Discussion
The problem of predicting malignant behavior in meningiomas has been widely discussed in the literature. 1, 4, 13, 20, 21, 26, 29, 31 The number of cases of atypical and malignant meningiomas discussed in the majority of papers are, however, quite small; the only large series was that of Jääskeläinen, et al., 13 who reported a series of 53 atypical and malignant meningiomas. Whereas benign meningioma tend to show a preponderance in females, atypical and malignant meningiomas tend to show a preponderance in males.
14,21,29,36,38 Our series, which showed a 64% preponderance in males for aggressive meningeal tumors, is consistent with the literature.
Histological Classification
The many discussions of meningiomas in the literature agree little on the histological features that differentiate atypical meningioma, malignant meningioma, and meningeal sarcoma. The histopathology of meningeal hemangiopericytoma is similar to that of its systemic counterpart, but may not be recognized as readily in an intracranial location. 8, 9, 36 We have attempted to describe the histopathological criteria that are associated with each type of lesion. The separation of hemangiopericytoma from meningioma is supported by the in vivo studies of Kawano, et al., 16 who used immunohistochemical analysis and electron microscopy to conclude that hemangiopericytoma is more similar to vascular and perivascular tissues than to meningothelial cells and is, thereby, distinguishable from meningioma. We also believe that meningeal sarcoma cannot be classified as meningioma, for there is usually no histological confirmation that this tumor arose from meningothelial cells. Although both hemangiopericytoma and meningeal sarcoma may be erroneously diagnosed as malignant meningioma, as was the case for some patients in our series, these tumors are indeed distinct entities.
Role of BUdR LI
Because of the uncertain and unpredictable clinical behavior of these tumors, some researchers have studied the use of tumor proliferative indices to determine the proliferative capacity of the tumor and to predict the time to tumor recurrence. One of the most reliable and reproducible indices involves the use of a BUdR. It has been demonstrated that tumors with a BUdR of 1% or more recur more rapidly. 5, 10, 12, 18, 29, 32 Dinda, et al., 5 recently found that recurrent and malignant meningiomas exhibited a higher LI (means 2.6% Ϯ 0.5% and 2.8% Ϯ 0.4%, respectively) than benign nonrecurrent meningiomas (mean 0.6% Ϯ 0.3%). Lee, et al., 18 found a recurrence rate of 100% for patients with an LI of more than 5% and a recurrence rate of 44% in those with an LI between 1% and 5%. Both studies suggest that BUdR LI is a reliable indicator of how rapidly a meningioma will recur.
Using logarithmic regression analysis, Shibuya and colleagues 32 determined that the time to reoperation (in months) for a completely resected tumor with a given BUdR LI can be calculated as 70.0 ϫ LI(%) Ϫ1.2 In our series, two patients for whom BUdR LI values were available have experienced recurrences that could have been accurately predicted by Shibuya's equation: 1) Case 16 (initial LI = 5.8% that predicted recurrence in approximately 8.5 months; actual recurrence occurred at 10 months); and 2) Case 19 (initial LI = 3.1%, experienced recurrence of the tumor at 17 months following resection). Case 14, who had a tumor of LI 4.3% on first recurrence and, according to the equation, should have had another recurrence in approximately 12 months, had not experienced tumor recurrence at 18 months following resection.
The data indicate that BUdR would be helpful as a diagnostic aid to be used in conjunction with histological features in studying meningeal tumors. The tumors we describe were diagnosed only on the basis of their histopathological features, even when a BUdR LI was available. If a BUdR LI were incorporated into the diagnostic process on a routine basis, as suggested by the aforementioned studies of Dinda, et al., 5 Lee, et al., 18 and Shibuya, et al., 32 the potential for tumor recurrence might be better estimated than by using the histological features alone.
Radiological Features
We are in accord with the conclusions of Servo, et al., 31 who determined that CT cannot reliably distinguish malignant meningiomas from benign ones. A review of the literature, including the present study, indicates that there are, however, some CT trends that should be noted. 3, [21] [22] [23] 31 The absence of visible calcium aggregates, for example, is considered to be typical of malignant meningiomas, 4,25 although Servo and colleagues found calcifications in 8% of their series of malignant meningiomas. Calcification was not observed in any of the patients in this series.
Mushrooming, defined as the presence of a prominent pannus of tumor extending well away from the globoid mass, was found by New, et al., 22 in five of their seven cases and was considered a useful sign. Alvarez, et al., 1 on the other hand, did not find this CT feature to be significant. In our study, mushrooming was seen in 11 of 23 patients (47.8%) with atypical meningioma, malignant meningioma, or meningeal sarcoma; however, it was not found in the hemangiopericytomas. Jääskeläinen, et al., 13 found mushrooming in 67% of his patients with atypical or malignant meningioma, and Rohringer, et al., 25 had similar results. Although we have no control group of benign meningiomas, our study does support the usefulness of this radiological finding.
Several authors have discussed the significance of contrast enhancement with respect to these tumors. Servo, et al., 31 found homogeneous enhancement almost uniformly in a series of benign, atypical, and malignant meningiomas, yet Jääskeläinen, et al., 13 observed nonhomogeneous enhancement in 42% of their series of atypical and malignant meningiomas. A distinct pattern of heterogeneity/homogeneity could not be distinguished in this study.
Tumor density has been discussed in the literature as a radiological feature associated with malignancy in meningioma. 22, 25, 31 In our study, CT revealed tumor isodensity in 66.7% of the atypical meningiomas and hyperdensity in 41.7% of the malignant meningiomas. The presence of hypodensity in only one tumor in the series, a malignant meningioma, differs from the finding of hypodense areas in 10 of 12 atypical or malignant meningiomas in the study by Alvarez, et al. 1 Another controversial CT feature in relation to malignancy is the presence of marked peritumoral edema. Slight-to-moderate edema has been associated with malignancy, 22, 25, 31 and some studies found that massive edema was associated with aggressive behavior. 6, 24 In our series, however, one-third of the patients with malignant meningioma and, thus, probable brain invasion, had no cerebral edema. These data suggest that the presence of edema does not necessarily indicate a malignant lesion and the absence of edema does not necessarily exclude malignancy.
Researchers have correlated osteolysis with histological aggressiveness or malignancy. 11, 22, 37 In this series, six patients, at least one from each histological subtype, presented with osteolytic lesions. One individual with meningeal sarcoma and three patients with malignant meningioma presented with both osteolysis and a soft-tissue mass, findings that were discussed in more detail in a previous paper. 37 Intrinsic cystlike areas are rarely seen in benign meningiomas; thus, their presence has been suggested as an indicator of histological aggressiveness or malignancy. 22, 23, 31 In our series of aggressive meningeal tumors, however, only three cysts were seen.
An indistinct tumor-brain interface on CT and MR imaging may indicate brain invasion and has been associated with aggressive tumors. 1, 4, 6, 23, 31 Invasion of the brain is as difficult to determine radiologically as it is histologically: the invasion is often microscopic and sheathlike and, hence, can be easily missed on images that are 8 to 10 mm thick. Similarly, invasion can be easily missed in histological samples, which may not include tissue from specific areas in which invasion is present. Indistinct tumor margins, although perhaps an imperfect method of evaluating brain invasion, are still worth noting: indistinct margins were found in seven tumors in this series, most notably in six of 12 histologically malignant meningiomas. Thus, the presence of indistinct tumor margins on CT or MR images remains a suggestive sign of malignancy.
Magnetic resonance imaging is increasingly being used to attempt to obtain preoperative tissue-typing of meningiomas, with varying results: some studies have reported 75% to 96% accuracy, 6, 15 whereas others find no correlation. 3, 34 The MR characteristics that allowed accurate preoperative identification of meningioma subtypes were confined to findings on T 2 -weighted images; meningothelial and angioblastic variants were found to have a persistently higher signal intensity on T 2 -weighted sequences than did fibroblastic and transitional meningiomas, which demonstrated a higher relative signal intensity on intermediate images. Of the malignant meningiomas studied by Elster, et al., 7 no significant difference could be detected on either T 1 -weighted or T 2 -weighted studies, which allowed differentiation from benign meningiomas.
Significance of Metastasis
Although the presence of metastasis is not an invariable sign of histological malignancy in meningioma, the vast majority of metastases do arise from aggressive and malignant tumors. 19, 27, 29 In this study, metastases were present in 24% of the patients and in each histological subtype.
The lung and the musculoskeletal system have been reported as the most common sites of metastasis from these aggressive meningeal tumors. 9, 19, 29, 33 The most common sites of metastasis in our series were lung and bone, and one patient with meningeal sarcoma had diffuse metastases to multiple organs.
Therapy, Survival, and Recurrence
The small sample of patients in our study limits the conclusions that can be drawn, although the finding that patients with malignant meningioma survived longer than those with atypical meningioma is interesting. This peculiar finding is further evidence that diagnoses based on histological features alone may be unreliable for predicting clinical course.
The number of patients who underwent a subtotal resection at the first presentation is small; however, the survival rate of those patients was significantly shorter than those who had total tumor resections. Of course, it is important to note that patients have subtotal resections only when total resections are deemed too dangerous, which suggests that the choice of subtotal resection in those patients may have biased the data by including patients with worse prognoses. In any case, the goal of surgical resection for aggressive meningeal tumors certainly should be radical resection of the entire tumor mass, along with any involved dura and bone.
There is little discussion in the literature on the specific issue of radiation therapy for aggressive meningeal tumors, but the published studies point to the benefit of radiation. 28, 29 Our data for radiation therapy indicate that postsurgical irradiation may not be as beneficial in aggressive meningeal tumors as it is in benign ones. This finding is supported by a recent review of atypical and malignant meningiomas by Mahmood, et al., 21 in which radiation did not prevent or retard tumor recurrence.
Chemotherapy regimens used in this study proved to be unsuccessful. Although Stewart, et al., 35 reported some success using doxorubicin, our patients showed no improvement with that or any other regimen. Further studies are necessary to develop rational and effective chemotherapy regimens for these tumors.
Conclusions
Hemangiopericytoma, meningeal sarcoma, atypical meningioma, and malignant meningioma are four distinct histological entities whose classification in the neurosurgical literature has historically been disputed. Classification based on histological features alone can be unreliable in evaluating tumor aggressiveness. Proliferation indices such as BUdR can be incorporated into the diagnostic procedure and may better predict the probable time-to-tumor recurrence. Whatever the classification of the tumor, the surgeon must bear in mind that all four are aggressive meningeal tumors with the propensity to metastasize and recur rapidly and should be treated aggressively. Surgical excision should be radical. Although the benefit of postoperative radiotherapy is questionable, it is still recommended. Traditional chemotherapy has proved ineffective; thus, new chemotherapeutic agents need to be developed.
